ClinicalTrials.gg
RecruitingNCT05910580Updated Jun 15, 2026

Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

An interventional study of Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Alcohol-Related Disorders, Substance-Related Disorders and Mental Health, sponsored by Emory University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Alcohol-Related Disorders with a site in United States — 13 open to participants now, 18 under way, 1 of them phase 3. Alcohol-Related Disorders · United States.

Planned enrollment
16th of 94
400 · median 86
Started
2025
with 5 others
No phase
48 of 107
7 open now
Primary completion
2027-05
later than 7 of 17 live
Registered
91st of 107
by date

Among the 107 studies in Alcohol-Related Disorders with a site in United States, this one is the 16th largest by planned enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2025, is one of 48 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 91st registered.

Alcohol-Related Disorders

156 studies on the registry are indexed under Alcohol-Related Disorders; 23 are open to participants now.

Browse Alcohol-Related Disorders studies →

Open to participants now

13 of the 107 studies in Alcohol-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Alcohol-Related Disorders studies recruiting now, 5 (31%) set no upper age limit and 7 (44%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Alcohol-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.

The main questions it aims to answer are:

  • Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?
  • Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?
  • Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?

Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.

Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.

Read the detailed description

Risky alcohol and drug use are associated with severe, negative, and long-term health outcomes and disparities, including sexual and reproductive health (SRH), among reproductive aged people in the United States. High rates and sequelae of alcohol and drug use disproportionately experienced by structurally marginalized groups shape lifelong health inequities for people of racial/ethnic minority, living in poverty, and residing in under-resourced and under-served communities. Among populations at risk of pregnancy-related sequelae (predominantly those self-identifying as women and thus this study's primary focus), harmful alcohol and substance use and alcohol use disorders (AUDs)/substance use disorders (SUDs) contribute to condom and contraceptive nonuse among those not intending pregnancy, sex while intoxicated, non-consensual sex, violence/rape, sexually transmitted infections, unintended pregnancy, and maternal and infant morbidity and mortality.

Family planning (FP) clinics are uniquely well-suited but entirely untapped sites for implementing and scaling integrated alcohol/substance use services. Largely community-based health centers that are publicly funded and/or serve Medicaid enrollees, FP clinics are a trusted care source and primary access point for reproductive aged women, and a safety net for the most socially disadvantaged groups. Yet few, if any, studies have rigorously evaluated interventions or implementation strategies to accelerate the uptake of alcohol/substance services in FP contexts. In obstetrics and HIV, widespread adoption of evidence-based SBIRT (screening, brief intervention, and referral to treatment) is precluded by multi-level barriers; data on specific challenges faced by FP providers are lacking. Virtually nothing is known about telemedicine, which has been rolled out for contraception and other routine visits during the pandemic, as a technological infrastructure for SBIRT. Whether and how the promising strategy of Implementation and Sustainment Facilitation (ISF) can bridge systems barriers and support scale up in FP settings is unknown.

The researchers of this study propose an explanatory, sequential, mixed methods study of alcohol and drug SBIRT in an expansive FP clinic network - a novel and highly impactful setting with a national reach of a diverse and largely structurally disadvantaged population of reproductive-aged women at greatest risk for AUDs/SUDs. The researchers will conduct a randomized Type 1 Hybrid Effectiveness-Implementation Trial within a large Northeastern regional affiliate and its four clinics of a national SRH care organization.

Results will inform an evidence-based, innovative, stakeholder-driven FP SBIRT model in response to the high-level calls for integrated women's health care. With concrete guidance for scaling alcohol/ drug services in SRH settings nationally, findings will promote women's health equity across the U.S.

03

Conditions studied

  • Alcohol-Related Disorders
  • Substance-Related Disorders
  • Mental Health
  • Reproductive Health
  • Sexual Health
  • Sexually Transmitted Diseases
  • Contraception
  • Maternal Health
  • Pregnancy
  • Women's Health

Keywords

  • Implementation Science
  • Mass Screening
  • Motivational Interviewing
  • Referral and Consultation
  • Quality of Health Care
  • Early Medical Intervention
  • Family Planning Services
  • Primary Health Care
  • Reproductive Health Services
  • Telemedicine
  • Preconception Care
  • Young Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 18 years
  • U.S. residing
  • Have internet access (own a computer or smart phone)
  • Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments

Exclusion criteria

Exclusion Criteria:

  • Not capable of communicating (reading, speaking, writing) in English or Spanish
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Screening, Brief Intervention, and Referral to Treatment (SBIRT)

    Patients at study clinics who are randomized to receive the Screening, Brief Intervention, and Referral to Treatment (SBIRT) intervention, which is delivered in-person and through telemedicine.

    Behavioral: Screening, Brief Intervention, and Referral to Treatment (SBIRT)

  • No intervention
    Usual Care

    Patients at study clinics who are randomized to receive usual care. None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.

Interventions

  • BehavioralScreening, Brief Intervention, and Referral to Treatment (SBIRT)

    Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.

06

What researchers measure

Primary outcomes

  1. Average Number of Drinks Per Drinking Day

    Participants are asked to self-report the number of drinks consumed on days when alcohol was consumed, during the past 30 days.

    Time frame: Baseline, Day 30, Month 3

  2. Number of Days of Drug Use

    Participants are asked to self-report the number of days of drug use in the past 30 days.

    Time frame: Baseline, Day 30, Month 3

  3. Incidence of sex under influence of alcohol/drugs

    Any incidence of sex under influence of alcohol/drugs in past 30 days.

    Time frame: Baseline, Day 30, Month 3

  4. Number of events of sex under influence of alcohol/drugs

    The number of events of sex while under influence of alcohol/drugs in past 30 days.

    Time frame: Baseline, Day 30, Month 3

  5. Patient Health Questionnaire (PHQ-9)

    The Patient Health Questionnaire (PHQ-9) is a 9-item instrument assessing symptoms of depression during the prior two weeks. Responses are given on a 4-point scale where 0 = not at all and 3 = nearly everyday. Total scores range from 0 to 27 where higher scores indicate greater feelings of depression. Scores of 0 to 4 indicate minimal depression, scores of 5 to 9 indicate mild depression, scores of 10 to 14 indicate moderate depression, scores of 15 to 19 indicate moderately severe depression, and scores of 20 or more indicate severe depression.

    Time frame: Baseline, Day 30, Month 3

  6. Number of Clinic Patients Receiving a Brief Intervention During Implementation Phase

    The number of patients in each clinic who screen positive receiving a brief intervention during the implementation phase of the study.

    Time frame: During the 12-month implementation phase

  7. Number of Clinic Patients Receiving a Brief Intervention During Sustainment Phase

    The number of patients in each clinic who screen positive who receive a brief intervention during the sustainment phase of the study.

    Time frame: During the 12-month sustainment phase

  8. Number of Providers Using SBIRT During Implementation Phase

    The number of providers in each clinic using SBIRT during the implementation phase.

    Time frame: During the 12-month implementation phase

  9. Number of Clinics Using SBIRT During Sustainment Phase

    The number of clinics using SBIRT during the sustainment phase.

    Time frame: During the 12-month sustainment phase

  10. Number of Providers Using SBIRT During Sustainment Phase

    The number of providers in each clinic using SBIRT during the sustainment phase.

    Time frame: During the 12-month sustainment phase

  11. Number of Completed BIOS Tracking Sheets to Achieve Competency

    The number of completed Brief Intervention Observation Sheets (BIOS) needed to achieve competency will be examined.

    Time frame: During the preparation phase

  12. Brief Intervention Observation Sheet (BIOS) Score

    Fidelity to the intervention is assessed as the mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS). The score per provider is determined from a sample of audio recorded brief interventions. Responses to items are recorded as a "yes" or "no" assessment of whether the steps of the brief intervention were completed. The total score is the number of "yes" items and can range from 0 to 10, with higher scores indicating more steps completed.

    Time frame: During the 12-month implementation phase

  13. Brief Intervention Observation Sheet (BIOS) Score - Motivational Style

    Fidelity to the intervention is assessed as the mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS). The score per provider is determined from a sample of audio recorded brief interventions. Item 11 assesses the overall motivational interviewing style used by the provider. Scores are rated on a 7-point scale where 1 = not at all and 7 = very effectively. Higher scores indicate greater motivational interviewing style.

    Time frame: During the 12-month implementation phase

Secondary outcomes

  1. Number of Days of Alcohol Use

    Participants are asked to self-report the number of days they consumed alcohol during the past 30 days.

    Time frame: Baseline, Day 30, Month 3

  2. Number of Days of Binge Drinking

    Participants are asked to self-report the number of days they consumed 4 or more alcoholic drinks per day during the past 30 days.

    Time frame: Baseline, Day 30, Month 3

  3. Alcohol Use Disorders Identification Test-Concise (AUDIT-C) Score

    The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a 3-item alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The questionnaire asks about drinking behavior in the past 30 days. Responses to items are given on a 5-point scale where 0 = never and 4 = the highest frequency of alcohol use or consumption per drinking day. Total scores range from 0 (non-drinkers) to 12. Higher scores indicate that a person's alcohol consumption is likely to affect his or her health and safety.

    Time frame: Baseline, Day 30, Month 3

  4. Drug Abuse Screening Test (DAST-10) Score

    The Drug Abuse Screening Test (DAST-10) is a 10-item instrument assessing drug use (not including alcohol and tobacco use). Each item is responded to as "yes" or "no" and the total score is the sum of all "yes" responses. Total scores range from 0 to 10 with a score of 0 indicating that no problems are reported and the degree of problems related to drug abuse increase as the total score increases. Scores of 1 or 2 indicate a low level of problems, scores of 3 to 5 indicate a moderate level of problems, scores of 6 to8 indicate substantial levels of problems, and scores of 9 and 10 indicate severe levels of problems related to drug abuse.

    Time frame: Baseline, Day 30, Month 3

  5. Incidence of condom nonuse

    Participants are asked to report any incidence of condom nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.

    Time frame: Baseline, Day 30, Month 3

  6. Number of events of condom nonuse

    Participants reporting condom nonuse are asked to report the number of events of condom nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.

    Time frame: Baseline, Day 30, Month 3

  7. Incidence of contraceptive nonuse

    Participants are asked to report any incidence of contraceptive nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.

    Time frame: Baseline, Day 30, Month 3

  8. Number of events of contraceptive nonuse

    Participants reporting contraception nonuse are asked to report the number of events of contraceptive nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.

    Time frame: Baseline, Day 30, Month 3

  9. Incidence of regretted/nonconsensual sex and sexual violence

    Participants are asked to report any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days.

    Time frame: Baseline, Day 30, Month 3

  10. Number of events of regretted/nonconsensual sex and sexual violence

    Participants reporting non-consensual sex, regretted sex, or sexual violence in past 30 days are asked to report the number of events.

    Time frame: Baseline, Day 30, Month 3

  11. Unintended pregnancy

    Participants are asked to report any incidence of unintended pregnancy occurring in the past 30 days.

    Time frame: Baseline, Day 30, Month 3

  12. Generalized Anxiety Disorder 7-item (GAD-7) Scale Score

    The Generalized Anxiety Disorder 7-item (GAD-7) instrument is a well-validated patient self-report scale measuring anxiety severity. Participants respond to statements to indicate how often they have been bothered by specified symptoms of anxiety (such as "feeling nervous, anxious, or on edge). Response choices include 0 = not at all sure, 1 = several days, 2 = over half the days, and 3 = nearly every day. Total scores range from 0 to 21 with higher scores indicating increased anxiety. A score of 0 to 4 indicates minimal anxiety, scores of 5 to 9 indicate mild anxiety, scores of 10 to 14 indicate moderate anxiety, and scores of 15 to 21 indicate severe anxiety.

    Time frame: Baseline, Day 30, Month 3

  13. World Health Organization-Five Well-Being Index (WHO-5) Score

    The World Health Organization-Five Well-Being Index (WHO-5) a 5-item scale that measures subjective psychological well-being in past 14 days. Responses to items are given on a 6-point scale where 0 = at no time and 5 = all of the time. Total raw scores range from 0 to 25, with 0 representing the worst possible and 25 representing the best possible quality of life. Scores can also be multiplied by 4 to obtain a percentage score ranging from 0 to 100, where 0 represents the worst possible quality of life and 100 represents the best possible quality of life.

    Time frame: Baseline, Day 30, Month 3

  14. General Self-reported Health Score

    Likert rating of general self-reported health in past 30 days

    Time frame: Baseline, Day 30, Month 3

  15. 12-Item Short Form (SF-12) Health Survey Score

    Quality of life is assessed with the SF-12 Health Survey. The SF-12 is a multipurpose, standardized self-report short form survey with 12 questions assessing mental and physical functioning. The SF-12 consists of 12 items with a Likert-type response format that measures quality of life with a Physical Component Summary (PCS) and Mental Component Summary (MCS). Subscales associated with the PCS include physical functioning, role limitations due to physical problems, bodily pain, and general health perceptions. Subscales associated with the MCS include vitality (energy and fatigue), social functioning, role limitations due to emotional problems, and mental health. A scoring algorithm is used to generate a total score for each component ranging from 0 to 100. Low values represent a poor health state while high values represent a good health state.

    Time frame: Baseline, Day 30, Month 3

  16. Number of Patients Screened During Implementation Phase

    The number of patients, out of all patients seen at the study sites, who are screened during the implementation phase.

    Time frame: During the 12-month implementation phase

  17. Number of Patients Screened During Sustainment Phase

    The number of patients, out of all patients seen at the study sites, who are screened during the sustainment phase.

    Time frame: During the 12-month sustainment phase

  18. Number of Patients Receiving Referral During Implementation Phase

    The number of patients who screen at a severe level of alcohol use, who receive a referral during the implementation phase.

    Time frame: During the 12-month implementation phase

  19. Number of Patients Receiving Referral During Sustainment Phase

    The number of patients who screen at a severe level of alcohol use, who receive a referral during the sustainment phase.

    Time frame: During the 12-month sustainment phase

  20. University of Missouri-Kansas City Screening & Brief Intervention Knowledge Assessment Score

    SBIRT knowledge is assessed with the University of Missouri-Kansas City Screening \& Brief Intervention Knowledge Assessment. This instrument will be completed by providers undergoing training in SBIRT. Scores range from 0-20, with higher scores indicating more knowledge of SBIRT.

    Time frame: During the implementation phase

  21. Brief Intervention Observation Sheet (BIOS) Score During Preparation Phase

    Fidelity to the intervention is assessed as the mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS), from the last observation conducted during provider training. The score per provider is determined from a sample of audio recorded brief interventions. Responses to items are recorded as a "yes" or "no" assessment of whether the steps of the brief intervention were completed. The total score is the number of "yes" items and can range from 0 to 10, with higher scores indicating more steps completed.

    Time frame: During the preparation and implementation phases

  22. Brief Intervention Observation Sheet (BIOS) Score - Motivational Style

    Fidelity to the intervention is assessed as the mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS), from the last observation conducted during provider training. The score per provider is determined from a sample of audio recorded brief interventions. Item 11 assesses the overall motivational interviewing style used by the provider. Scores are rated on a 7-point scale where 1 = not at all and 7 = very effectively. Higher scores indicate greater motivational interviewing style.

    Time frame: During the preparation and implementation phases

Other outcomes

  1. Number of Participants with STI Diagnosis

    The number of participants receiving a diagnosis of one more sexually transmitted infections (STIs) in past 30 days.

    Time frame: Baseline, Day 30, Month 3

  2. Past or current receipt of substance use treatment or services

    Number of days/times the participant received treatment or counseling for alcohol or drugs or attended a self-help/mutual support meeting in past 30 days

    Time frame: Baseline, Day 30, Month 3

07

Study locations

4 of 4 sites recruiting
  • Greater Boston Health Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • Metro West Health Center
    Marlborough, Massachusetts 01752, United States
    Recruiting
  • Western Massachusetts Health Center
    Springfield, Massachusetts 01107, United States
    Recruiting
  • Central Massachusetts Health Center
    Worcester, Massachusetts 01609, United States
    Recruiting
08

References and documents

Publications

  • Tan CH, Denny CH, Cheal NE, Sniezek JE, Kanny D. Alcohol use and binge drinking among women of childbearing age - United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2015 Sep 25;64(37):1042-6. doi: 10.15585/mmwr.mm6437a3. PubMed 26401713 ↗
  • Naimi TS, Lipscomb LE, Brewer RD, Gilbert BC. Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics. 2003 May;111(5 Pt 2):1136-41. PubMed 12728126 ↗
  • Thomas AG, Brodine SK, Shaffer R, Shafer MA, Boyer CB, Putnam S, Schachter J. Chlamydial infection and unplanned pregnancy in women with ready access to health care. Obstet Gynecol. 2001 Dec;98(6):1117-23. PubMed 11755563 ↗
  • Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol Alcohol. 2002 Jan-Feb;37(1):87-92. doi: 10.1093/alcalc/37.1.87. PubMed 11825863 ↗
  • Iyasu S, Randall LL, Welty TK, Hsia J, Kinney HC, Mandell F, McClain M, Randall B, Habbe D, Wilson H, Willinger M. Risk factors for sudden infant death syndrome among northern plains Indians. JAMA. 2002 Dec 4;288(21):2717-23. doi: 10.1001/jama.288.21.2717. PubMed 12460095 ↗
  • Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, Martin PR. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011 Mar;40(2):199-202. doi: 10.1016/j.jsat.2010.08.011. Epub 2010 Oct 30. PubMed 21036512 ↗
  • Ko JY, Wolicki S, Barfield WD, Patrick SW, Broussard CS, Yonkers KA, Naimon R, Iskander J. CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):242-245. doi: 10.15585/mmwr.mm6609a2. PubMed 28278146 ↗
  • National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic. Washington (DC): National Academies Press (US); 2020 Jan 23. Available from http://www.ncbi.nlm.nih.gov/books/NBK555809/ PubMed 32293827 ↗
  • Terplan M, Lawental M, Connah MB, Martin CE. Reproductive Health Needs Among Substance Use Disorder Treatment Clients. J Addict Med. 2016 Jan-Feb;10(1):20-5. doi: 10.1097/ADM.0000000000000175. PubMed 26690290 ↗
  • Cornford CS, Close HJ, Bray R, Beere D, Mason JM. Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study. PLoS One. 2015 Mar 4;10(3):e0116231. doi: 10.1371/journal.pone.0116231. eCollection 2015. PubMed 25739018 ↗
  • Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications. Clin Perinatol. 2013 Sep;40(3):337-50. doi: 10.1016/j.clp.2013.05.015. Epub 2013 Jul 4. PubMed 23972743 ↗
  • Kellogg A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol. 2011 Mar;204(3):259.e1-4. doi: 10.1016/j.ajog.2010.12.050. PubMed 21376165 ↗
  • Pinedo M. Help seeking behaviors of Latinos with substance use disorders who perceive a need for treatment: Substance abuse versus mental health treatment services. J Subst Abuse Treat. 2020 Feb;109:41-45. doi: 10.1016/j.jsat.2019.11.006. Epub 2019 Nov 14. PubMed 31856949 ↗
  • Hadland SE, Copelas SH, Harris SK. Trajectories of Substance Use Frequency among Adolescents Seen in Primary Care: Implications for Screening. J Pediatr. 2017 May;184:178-185. doi: 10.1016/j.jpeds.2017.01.033. Epub 2017 Feb 10. PubMed 28196680 ↗
  • Chavez LJ, Kelleher KJ, Matson SC, Wickizer TM, Chisolm DJ. Mental Health and Substance Use Care Among Young Adults Before and After Affordable Care Act (ACA) Implementation: A Rural and Urban Comparison. J Rural Health. 2018 Dec;34(1):42-47. doi: 10.1111/jrh.12258. Epub 2017 Jul 7. PubMed 28685885 ↗
  • Robbins C, Boulet SL, Morgan I, D'Angelo DV, Zapata LB, Morrow B, Sharma A, Kroelinger CD. Disparities in Preconception Health Indicators - Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014. MMWR Surveill Summ. 2018 Jan 19;67(1):1-16. doi: 10.15585/mmwr.ss6701a1. PubMed 29346340 ↗
  • Hayes DK, Robbins CL, Ko JY. Trends in Selected Chronic Conditions and Related Risk Factors Among Women of Reproductive Age: Behavioral Risk Factor Surveillance System, 2011-2017. J Womens Health (Larchmt). 2020 Dec;29(12):1576-1585. doi: 10.1089/jwh.2019.8275. Epub 2020 May 22. PubMed 32456604 ↗
  • Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, Moresky RT, Martinez ME, McGovern T. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet. 2020 Apr 11;395(10231):1175-1177. doi: 10.1016/S0140-6736(20)30801-1. No abstract available. PubMed 32278371 ↗
  • ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012 May;119(5):1070-6. doi: 10.1097/AOG.0b013e318256496e. PubMed 22525931 ↗
  • Frost JJ, Gold RB, Bucek A. Specialized family planning clinics in the United States: why women choose them and their role in meeting women's health care needs. Womens Health Issues. 2012 Nov-Dec;22(6):e519-25. doi: 10.1016/j.whi.2012.09.002. PubMed 23122212 ↗
  • Hall KS, Harris LH, Dalton VK. Women's Preferred Sources for Primary and Mental Health Care: Implications for Reproductive Health Providers. Womens Health Issues. 2017 Mar-Apr;27(2):196-205. doi: 10.1016/j.whi.2016.09.014. Epub 2016 Nov 4. PubMed 27825589 ↗
  • Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000 Feb;15(2):84-91. doi: 10.1046/j.1525-1497.2000.03379.x. PubMed 10672110 ↗
  • Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, Creanga AA. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016 Nov;215(5):539-547. doi: 10.1016/j.ajog.2016.06.038. Epub 2016 Jul 1. PubMed 27373599 ↗
  • Rahm AK, Boggs JM, Martin C, Price DW, Beck A, Backer TE, Dearing JW. Facilitators and Barriers to Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Primary Care in Integrated Health Care Settings. Subst Abus. 2015;36(3):281-8. doi: 10.1080/08897077.2014.951140. Epub 2014 Aug 15. PubMed 25127073 ↗
  • Hettema J, Cockrell S, Russo J, Corder-Mabe J, Yowell-Many A, Chisholm C, Ingersoll K. Missed Opportunities: Screening and Brief Intervention for Risky Alcohol Use in Women's Health Settings. J Womens Health (Larchmt). 2015 Aug;24(8):648-54. doi: 10.1089/jwh.2014.4961. Epub 2015 Jul 31. PubMed 26230758 ↗
  • Goldstein KM, Zullig LL, Dedert EA, Alishahi Tabriz A, Brearly TW, Raitz G, Sata SS, Whited JD, Bosworth HB, Gordon AM, Nagi A, Williams JW Jr, Gierisch JM. Telehealth Interventions Designed for Women: an Evidence Map. J Gen Intern Med. 2018 Dec;33(12):2191-2200. doi: 10.1007/s11606-018-4655-8. Epub 2018 Oct 3. PubMed 30284173 ↗
  • Boudreaux ED, Haskins B, Harralson T, Bernstein E. The remote brief intervention and referral to treatment model: Development, functionality, acceptability, and feasibility. Drug Alcohol Depend. 2015 Oct 1;155:236-42. doi: 10.1016/j.drugalcdep.2015.07.014. Epub 2015 Jul 23. PubMed 26297297 ↗
  • Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, Madden LM, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial. Addict Sci Clin Pract. 2021 Oct 12;16(1):61. doi: 10.1186/s13722-021-00268-0. PubMed 34635178 ↗
  • Garner BR, Zehner M, Roosa MR, Martino S, Gotham HJ, Ball EL, Stilen P, Speck K, Vandersloot D, Rieckmann TR, Chaple M, Martin EG, Kaiser D, Ford JH 2nd. Testing the implementation and sustainment facilitation (ISF) strategy as an effective adjunct to the Addiction Technology Transfer Center (ATTC) strategy: study protocol for a cluster randomized trial. Addict Sci Clin Pract. 2017 Nov 17;12(1):32. doi: 10.1186/s13722-017-0096-7. PubMed 29149909 ↗
  • Garner BR, Gotham HJ, Chaple M, Martino S, Ford Ii JH, Roosa MR, Speck KJ, Vandersloot D, Bradshaw M, Ball EL, Toro AK, Griggs C, Tueller SJ. The implementation and sustainment facilitation strategy improved implementation effectiveness and intervention effectiveness: Results from a cluster-randomized, type 2 hybrid trial. Implement Res Pract. 2020 Jan-Dec;1:2633489520948073. doi: 10.1177/2633489520948073. Epub 2020 Sep 7. PubMed 36189179 ↗
  • Gotham HJ, Wilson K, Carlson K, Rodriguez G, Kuofie A, Witt J. Implementing Substance Use Screening in Family Planning. J Nurse Pract. 2019;15(4):306-310.

Individual participant data

Plan to share: Yes — Per the NIAAA Exemption Request Committee's determination electronic health records/administrative records data components will not be shared. Quantitative survey data will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be made available for sharing following publication of finding from this study and will be available indefinitely.

Access criteria: Anyone who wishes to access the data will be able to do so.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 49 non-industry interventional studies with no phase under Alcohol-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 44. This study's planned 22 months is below that.

Counting every sponsor, half of 49 studies reached it within 30 months; a quarter within 17 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
Jun 18, 2023
StartActual
Jul 3, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05910580
Lead sponsor
Emory University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA), Stanford University, Planned Parenthood League of Massachusetts
Responsible party
Justine Welsh (Associate Professor, Emory University) — Principal investigator
First posted
Jun 18, 2023
Start date
Jul 3, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Kelli S Hall, PhD MS
Contact
ksh2110@cumc.columbia.edu
212-305-4805
Jessica LaHote, MPH
Contact
jl5348@cumc.columbia.edu
212-305-4805
Kelli S Hall, MD
principal investigator · Columbia University
Justine Welsh, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion